STAT

Every data point has a face: What Michael Becker taught us

Michael Becker, the patient advocate and former biotech CEO who passed away this week, urged audiences to think beyond the word “data” when talking about studies of patients.

Michael Becker was a biotech executive before he was a patient advocate. When he discovered he had head and neck cancer, he decided to go public, and in doing so made an impact — both within the drug industry and beyond.

Cancer, Becker once said, takes away a lot more than it gives. But he wanted his own experience to show people the risks of the human papillomavirus, which caused his disease,, according to the Centers for Disease Control and Prevention. In total, the HPV virus is estimated to cause 34,000 cancers annually, including cancers of the cervix and genitals.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks